RxDoctor Payments Data

Michael Prater, MD

Otolaryngology · Lake Havasu City, AZNPI 1598723173

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Sanofi at 25.2% of the total. 2025 is the largest year on record at $446, more than ten times the $27 reported in 2019.

$1,871in general payments, 2019–2025

Across 91 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$471
  • GSK$424
  • Regeneron Healthcare Solutions, Inc.$346
  • Optinose US, Inc.$215
  • Baxter Healthcare$75
  • Merck$55
  • plus $286 from 13 others

What the payments were for

  • Food & beverage$1,871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,871 in reported general payments places this provider in the 60th percentile of 150 otolaryngology providers in Arizona.

See all otolaryngology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,464,694
Medicare patients
1,394
Services billed
12,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab48$219,081
Levothyroxine Sodium523$3,780
Fluticasone Propionate255$3,454
Ipratropium Bromide133$3,139
Famotidine377$1,778
Ofloxacin99$1,349
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav95$1,014
SynthroidLevothyroxine Sodium30$613
Montelukast Sodium87$604
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen74$496
Calcitriol13$432
Fluocinolone Acetonide Oil15$402
Acetic Acid20$360
Methimazole69$323
Lidocaine Hcl ViscousLidocaine Hcl13$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$19$61330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 150 otolaryngology providers in Arizona.

Other otolaryngology in Lake Havasu City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →